Eton Pharmaceuticals, Inc. 8-K

What Happened Eton Pharmaceuticals, Inc. (ETON) filed a Form 8-K reporting the results of its virtual Annual Meeting held June 9, 2026. Stockholders elected Jenn Adams and Charles J. Casamento as directors for three‑year terms. The company’s stockholders also ratified the appointment of Grant Thornton LLP as Eton’s independent registered public accounting firm for the year ending December 31, 2026.

Key Details

• Director election votes: Jenn Adams — For: 13,370,948; Withheld: 2,149,317; Broker non‑votes: 4,664,035. Charles J. Casamento — For: 9,925,548; Withheld: 5,594,717; Broker non‑votes: 4,664,035.
• Auditor ratification vote: Grant Thornton LLP — For: 16,942,328; Against: 3,236,671; Abstain: 5,301.
• Meeting date and form: Annual Meeting held virtually on June 9, 2026; results disclosed in an 8‑K (Item 5.07).

Why It Matters

• Confirming directors provides clarity on board composition and continuity of corporate governance, which can affect strategic oversight and investor confidence.
• Ratifying Grant Thornton as the independent auditor establishes who will conduct Eton’s audits for the 2026 fiscal year, relevant to financial reporting and audit oversight.
• These are governance actions (not operational or financial results) but are material to shareholders monitoring board makeup and audit arrangements.